A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China
← catalyst calendarNCT06548568 · readout ≤ 254 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
110estimated
Sites
13
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-13 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetic Macular Edema
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment Emergent Adverse Events (TEAEs), including Adverse Events of Special Interest (AESIs)
measured Up to approximately 24 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed